Status:
COMPLETED
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
Lead Sponsor:
Novartis
Collaborating Sponsors:
Daiichi Sankyo Co., Ltd.
Conditions:
Asthma
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
Eligibility Criteria
Inclusion
- Allergic asthma patients
- Inadequately controlled patients
Exclusion
- \- History of severe anaphylactoid or anaphylactic reactions
- Previous treatment with omalizumab
- History of cancer or cancer
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2006
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT00219323
Start Date
November 1 2003
End Date
March 1 2006
Last Update
October 25 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
This study is not being conducted in the United States
Tokyo, Japan